Natera, Inc. (NTRA)
| Market Cap | 31.07B +44.0% |
| Revenue (ttm) | 2.50B +36.6% |
| Net Income | -226.32M |
| EPS | -1.64 |
| Shares Out | 143.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,017,025 |
| Open | 213.64 |
| Previous Close | 212.07 |
| Day's Range | 209.57 - 219.44 |
| 52-Week Range | 131.81 - 256.36 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 260.05 (+19.86%) |
| Earnings Date | May 7, 2026 |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo... [Read more]
Financial Performance
In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for NTRA stock is "Buy." The 12-month stock price target is $260.05, which is an increase of 19.86% from the latest price.
News
Natera resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Natera (NTRA) with an Outperform rating and $275 price target The firm’s “constructive view” reflects Natera’s growth opportunities in minimal residual disease monitori...
Natera Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and an equity plan amendment, with all proposals approved by shareholders. No questions were raised, and final vote results will be published in a Form 8-K.
Natera Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Record Q1 performance led to raised revenue and margin guidance, with strong growth in Signatera and women's health. Robust clinical data and new product launches, including Fetal Focus and Latitude, support market leadership. Accelerated early cancer detection pipeline and international expansion signal long-term growth.
Natera initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Evie Koslosky initiated coverage of Natera (NTRA) with a Neutral rating and $245 price target The firm views Natera as the current leader in the molecular residual…
Natera, CytoDyn collaborate to advance ctDNA-guided development
Natera (NTRA) and CytoDyn Inc. (CYDY) announced a strategic collaboration to evaluate circulating tumor DNA dynamics and generate real-world molecular insights to support CytoDyn’s metastatic colorect...
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
AUSTIN, Texas & VANCOUVER, Wash.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage on...
Natera appoints Lynch, Rubin to board of directors
Natera (NTRA) announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company’s board of directors.
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to t...
Natera assumed with an Outperform at Wolfe Research
Wolfe Research analyst Paige Chamberlain assumed coverage of Natera (NTRA) with an Outperform rating and price target of $260, down from $275. As molecular residual disease “becomes more mainstream,” ...
CareDx denied request to Supreme Court to revive Natera award
A writ of certiorari was denied by the U.S. Supreme Court in the case of CareDx (CDNA) v. Natera (NTRA), meaning that the Court has declined to hear the appeal,…
Natera announces collaboration with Diakonos Oncology for Signatera in RM
Natera (NTRA) announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the ...
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage...
Natera enrolls first patients in SIGNAL-ER 101 study
Natera (NTRA) announced enrollment of the first patients in SIgnatera-Guided iNterventionAL-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early...
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionA...
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive p...
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of ...
Natera announces expansion into Austin, creating largest sequencing factory
Natera (NTRA) announced a significant expansion of its operations. At its North Austin headquarters campus, Natera will unveil two major expansion projects: a sequencing facility, significantly increa...
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milesto...
Natera announces Expand trial enrolled over 2,000 patients
Natera (NTRA) announced that the Expand clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months. Expand is a prospective, blinded, multi-site clinical tria...
EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2...
Signatera CDx approved by FDA as companion diagnostic in MIBC
Natera (NTRA) announced that the U.S. Food and Drug Administration has approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab immunotherapy in MIBC. “This is the first…
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Sign...
The Cancer Test That Wall Street Is Betting On
One company has a big early lead in blood tests that detect cancer returning in survivors.
Cathie Wood’s ARK Investment buys 17.3K shares of Natera today
21:34 EDT Cathie Wood’s ARK Investment buys 17.3K shares of Natera (NTRA) today
Natera price target raised to $249 from $240 at Piper Sandler
Piper Sandler raised the firm’s price target on Natera (NTRA) to $249 from $240 and keeps an Overweight rating on the shares. The firm notes the company has $1B in…